Cannabis and the Gastrointestinal Tract

Abstract

Cannabis has been used for its medicinal purposes since ancient times. Its consumption leads to the activation of Cannabis receptors CB1 and CB2 that, through specific mechanisms can lead to modulation and progression of inflammation or repair. The novel findings are linked to the medical use of Cannabis in gastrointestinal (GI) system. PURPOSE: The objective of the present paper is to elucidate the role of Cannabis consumption in GI system. An additional aim is to review the information on the function of Cannabis in non-alcoholic fatty liver disease (NAFLD). METHODS AND RESULTS: This review summarizes the recent findings on the role of cannabinoid receptors, their synthetic or natural ligands, as well as their metabolizing enzymes in normal GI function and its disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and possible adverse events. The synergism or antagonism between Cannabis’ active ingredients and the “entourage” plays a role in the efficacy of various strains. Some elements of Cannabis may alter disease severity as over-activation of Cannabis receptors CB1 and CB2 can lead to changes of the commensal gut flora. The endocannabinoid system (ECS) contributes to gut homeostasis. The ability of ECS to modulate inflammatory responses demonstrates the capacity of ECS to preserve gastrointestinal (GI) function. Alterations of the ECS may predispose patients to pathologic disorders, including IBD. Clinical studies in IBD demonstrate that subjects benefit from Cannabis consumption as seen through a reduction of the IBD-inflammation, as well as through a decreased need for other medication. NAFLD is characterized by fat accumulation in the liver. The occurrence of inflammation in NAFLD leads to non-alcoholic-steatohepatitis (NASH). The use of Cannabis might reduce liver inflammation. CONCLUSIONS: With limited evidence of efficacy and safety of Cannabis in IBD, IBS, and NAFLD, randomized controlled studies are required to examine its therapeutic efficacy. Moreover, since long term use of the plant leads to drug use disorders the patients should be followed continuously.

Cannabidiol Strengthening of Gastric Tight Junction Complexes Analyzed in an Improved Xenopus Oocyte Assay

“…Currently, the research on individual components of the plant is ongoing. The most well-known secondary plant extract is cannabidiol (CBD) [ 33 , 34 , 35 , 36 ]. In a latest study, CBD’s effects on GABAergic neurotransmission were investigated in Xenopus oocytes after microtransplanting human brain membranes [ 37 ].…”

Clearing up the smoke: Physical and mental health considerations regarding cannabis use in adolescents with cystic fibrosis

“…Further research is needed to understand the effects of cannabis use on hepatic function and pathology. Studies regarding possible uses of cannabis in the treatment of conditions such as IBD, irritable bowel syndrome, and nonalcoholic fatty acid liver disease are needed to further investigate its safety and efficacy 30 …”

“…Studies regarding possible uses of cannabis in the treatment of conditions such as IBD, irritable bowel syndrome, and nonalcoholic fatty acid liver disease are needed to further investigate its safety and efficacy. 30 …”

Cannabidiol attenuates inflammatory impairment of intestinal cells expanding biomaterial-based therapeutic approaches

“…In recent years, cannabidiol (CBD), one of the main secondary plant compounds of Cannabis sativa L., has been established as a novel compound for intestinal drug targeting and development [ [1] , [2] , [3] ]. Moreover, a combination of CBD with other biomaterials such as chitosan and alginate-based hydrogel has gained major attention [ 4 , 5 ].…”